Effrossyni Gkrania-Klotsas

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2840758/publications.pdf

Version: 2024-02-01

106 9,050 41
papers citations h-index

41 88 h-index g-index

48315

116 116 all docs citations

116 times ranked 17733 citing authors

#	Article	IF	CITATIONS
1	Acute kidney injury in patients hospitalized with COVID-19 from the ISARIC WHO CCP-UK Study: a prospective, multicentre cohort study. Nephrology Dialysis Transplantation, 2022, 37, 271-284.	0.7	48
2	The Removal of Airborne Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Other Microbial Bioaerosols by Air Filtration on Coronavirus Disease 2019 (COVID-19) Surge Units. Clinical Infectious Diseases, 2022, 75, e97-e101.	5.8	52
3	A2B-COVID: A Tool for Rapidly Evaluating Potential SARS-CoV-2 Transmission Events. Molecular Biology and Evolution, 2022, 39, .	8.9	12
4	Identification of host–pathogen-disease relationships using a scalable multiplex serology platform in UK Biobank. Nature Communications, 2022, 13, 1818.	12.8	28
5	Procalcitonin Is Not a Reliable Biomarker of Bacterial Coinfection in People With Coronavirus Disease 2019 Undergoing Microbiological Investigation at the Time of Hospital Admission. Open Forum Infectious Diseases, 2022, 9, ofac179.	0.9	10
6	The development, validation and application of remote blood sample collection in telehealth programmes. Journal of Telemedicine and Telecare, 2022, , 1357633X2210934.	2.7	7
7	Serious Infectious Complications After Rituximab Therapy in Patients With Autoimmunity: Is This the Final Word?. Clinical Infectious Diseases, 2021, 72, 738-742.	5.8	4
8	SARS-CoV-2 evolution during treatment of chronic infection. Nature, 2021, 592, 277-282.	27.8	802
9	Admission COVID-19 clinical risk assessment for guiding patient placement and diagnostic testing strategy. Clinical Medicine, 2021, 21, e140-e143.	1.9	1
10	Travel-related infections presenting in Europe: A 20-year analysis of EuroTravNet surveillance data. Lancet Regional Health - Europe, The, 2021, 1, 100001.	5. 6	27
11	Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet, The, 2021, 397, 605-612.	13.7	234
12	Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19. Science Immunology, 2021, 6, .	11.9	161
13	Machine Learning for COVID-19 Diagnosis and Prognostication: Lessons for Amplifying the Signal While Reducing the Noise. Radiology: Artificial Intelligence, 2021, 3, e210011.	5.8	24
14	Common pitfalls and recommendations for using machine learning to detect and prognosticate for COVID-19 using chest radiographs and CT scans. Nature Machine Intelligence, 2021, 3, 199-217.	16.0	607
15	Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK. Lancet Respiratory Medicine,the, 2021, 9, 699-711.	10.7	122
16	Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study. Lancet Respiratory Medicine, the, 2021, 9, 349-359.	10.7	161
17	Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet, The, 2021, 397, 1637-1645.	13.7	1,374
18	Multidrug-resistant tuberculosis imported into low-incidence countries—a GeoSentinel analysis, 2008–2020. Journal of Travel Medicine, 2021, 28, .	3.0	10

#	Article	IF	CITATIONS
19	Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet, The, 2021, 397, 2049-2059.	13.7	391
20	Importance of patient bed pathways and length of stay differences in predicting COVID-19 hospital bed occupancy in England. BMC Health Services Research, 2021, 21, 566.	2.2	22
21	Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK. Lancet Respiratory Medicine, the, 2021, 9, 773-785.	10.7	78
22	Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study. Lancet, The, 2021, 398, 223-237.	13.7	110
23	Neutralizing Anti-interferon- \hat{l}^3 Autoantibodies: an Ameliorating Factor in COVID-19 Infection?. Journal of Clinical Immunology, 2021, 41, 1531-1535.	3.8	5
24	Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study. Lancet Rheumatology, The, 2021, 3, e498-e506.	3.9	58
25	Superspreaders drive the largest outbreaks of hospital onset COVID-19 infections. ELife, 2021, 10, .	6.0	34
26	Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study. Lancet Microbe, The, 2021, 2, e354-e365.	7.3	216
27	Influenza: epidemiology and hospital management. Medicine, 2021, 49, 797-804.	0.4	11
28	A First Unexplained Invasive Encapsulated Bacterial Infection in Young Adults Associated With High Mortality and Readmission Rates. Clinical Infectious Diseases, 2020, 70, 528-530.	5.8	0
29	Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease. An International Multicenter Study. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1656-1665.	5.6	171
30	Combined Point-of-Care Nucleic Acid and Antibody Testing for SARS-CoV-2 following Emergence of D614G Spike Variant. Cell Reports Medicine, 2020, 1, 100099.	6.5	61
31	Primary pneumococcal peritonitis can be the first presentation of a familial complement factor I deficiency 1. Clinical and Experimental Immunology, 2020, 202, 379-383.	2.6	3
32	How achievable are COVID-19 clinical trial recruitment targets? A UK observational cohort study and trials registry analysis. BMJ Open, 2020, 10, e044566.	1.9	11
33	A safe approach to surgery for pituitary and skull base lesions during the COVID-19 pandemic. Acta Neurochirurgica, 2020, 162, 1509-1511.	1.7	22
34	ADA2 deficiency complicated by EBV-driven lymphoproliferative disease. Clinical Immunology, 2020, 215, 108443.	3.2	9
35	Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study. Lancet Psychiatry,the, 2020, 7, 875-882.	7.4	1,005
36	Analysis of scoring systems for primary immunodeficiency diagnosis in adult immunology clinics. Clinical and Experimental Immunology, 2020, 203, 47-54.	2.6	5

#	Article	IF	CITATIONS
37	Detection of neutralising antibodies to SARS-CoV-2 to determine population exposure in Scottish blood donors between March and May 2020. Eurosurveillance, 2020, 25, .	7.0	64
38	Cutaneous and mucocutaneous leishmaniasis in travellers and migrants: a 20-year GeoSentinel Surveillance Network analysis. Journal of Travel Medicine, 2019, 26, .	3.0	44
39	Perspectives on <i>Scedosporium</i> species and <i>Lomentospora prolificans</i> in lung transplantation: Results of an international practice survey from ESCMID fungal infection study group and study group for infections in compromised hosts, and European Confederation of Medical Mycology, Transplant Infectious Disease, 2019, 21, e13141.	1.7	24
40	Risk factors for herpes simplex virus type-1 infection and reactivation: Cross-sectional studies among EPIC-Norfolk participants. PLoS ONE, 2019, 14, e0215553.	2.5	15
41	115 Cerebral toxoplasmosis in a RA patient receiving biologic therapy. Rheumatology, 2019, 58, .	1.9	1
42	Business travel-associated illness: a GeoSentinel analysisâ€. Journal of Travel Medicine, 2018, 25, .	3.0	42
43	Emerging infectionsâ€"an increasingly important topic: review by the Emerging Infections Task Force. Clinical Microbiology and Infection, 2018, 24, 369-375.	6.0	44
44	Fatal breakthrough mucormycosis in a multivisceral transplant patient receiving micafungin: Case report and literature review. IDCases, 2018, 12, 76-79.	0.9	11
45	Toxoplasmosis in Transplant Recipients, Europe, 2010–2014. Emerging Infectious Diseases, 2018, 24, 1497-1504.	4.3	94
46	Epidemiological aspects of travel-related systemic endemic mycoses: a GeoSentinel analysis, 1997–2017. Journal of Travel Medicine, 2018, 25, .	3.0	27
47	Infectious diseases acquired by international travellers visiting the USAâ€. Journal of Travel Medicine, 2018, 25, .	3.0	13
48	<i>pfk13</i> -Independent Treatment Failure in Four Imported Cases of Plasmodium falciparum Malaria Treated with Artemether-Lumefantrine in the United Kingdom. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	91
49	Reply to Plucinski et al., "Interpreting Data from Passive Surveillance of Antimalarial Treatment Failuresâ€. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	0
50	Clostridium difficile infection in returning travellers. Journal of Travel Medicine, 2017, 24, .	3.0	27
51	Evaluating the Impact of Functional Genetic Variation on HIV-1 Control. Journal of Infectious Diseases, 2017, 216, 1063-1069.	4.0	20
52	Cytomegalovirus infection management in solid organ transplant recipients across European centers in the time of molecular diagnostics: An <scp>ESGICH</scp> survey. Transplant Infectious Disease, 2017, 19, e12773.	1.7	26
53	Incidence of Pneumocystis Jiroveci Pneumonia in Patients Following Intestinal Transplantation Transplantation, 2017, 101, S49.	1.0	1
54	Chronic norovirus infection and common variable immunodeficiency. Clinical and Experimental Immunology, 2017, 188, 363-370.	2.6	70

#	Article	IF	Citations
55	Malaria after international travel: a GeoSentinel analysis, 2003–2016. Malaria Journal, 2017, 16, 293.	2.3	74
56	Factors Affecting Mortality and Length of Stay Following Clostridium Difficile Associated Diarrhoea: Validating A Consistent Scoring System. Archives of Clinical Microbiology, 2017, 08, .	0.2	1
57	Cytomegalovirus Infection and Rates of Antiviral Resistance Following Intestinal and Multivisceral Transplantation. Transplantation Proceedings, 2016, 48, 492-496.	0.6	20
58	Emergence of host-adapted Salmonella Enteritidis through rapid evolution in an immunocompromised host. Nature Microbiology, 2016, 1 , .	13.3	86
59	The Extended Clinical Phenotype of 26 Patients with Chronic Mucocutaneous Candidiasis due to Gain-of-Function Mutations in STAT1. Journal of Clinical Immunology, 2016, 36, 73-84.	3.8	124
60	Measles in the 21st Century, a Continuing Preventable Risk to Travelers: Data From the GeoSentinel Global Network. Clinical Infectious Diseases, 2016, 62, 210-212.	5.8	25
61	Antibiotic prescribing and expenditures in outpatient adults in Greece, 2010 to 2013: evidence from real-world practice. Eurosurveillance, 2016, 21, .	7.0	19
62	Arboviral and other illnesses in travellers returning from Brazil, June 2013 to May 2016: implications for the 2016 Olympic and Paralympic Games. Eurosurveillance, 2016, 21, .	7.0	8
63	The Role Of Chronic Norovirus Infection In The Enteropathy Associated With Common Variable Immunodeficiency. American Journal of Gastroenterology, 2015, 110, 320-327.	0.4	95
64	Differential Diagnosis of Illness in Travelers Arriving From Sierra Leone, Liberia, or Guinea: A Cross-sectional Study From the GeoSentinel Surveillance Network. Annals of Internal Medicine, 2015, 162, 757-764.	3.9	34
65	Animal-Associated Exposure to Rabies Virus among Travelers, 1997–2012. Emerging Infectious Diseases, 2015, 21, 569-577.	4.3	48
66	Earlier detection of drug resistant mutations in small bowel/multivisceral transplant recipients with CMV infection using next generation sequencing. Journal of Infection, 2015, 71, 686.	3.3	0
67	Travel-associated infection presenting in Europe (2008–12): an analysis of EuroTravNet longitudinal, surveillance data, and evaluation of the effect of the pre-travel consultation. Lancet Infectious Diseases, The, 2015, 15, 55-64.	9.1	206
68	Regional Variation in Travel-related Illness acquired in Africa, March 1997–May 2011. Emerging Infectious Diseases, 2014, 20, 532-541.	4.3	37
69	1128Association between Cytomegalovirus Seropositivity or Titres and Cardiovascular Disease: Systematic Review and Meta-Analysis of Prospective Evidence. Open Forum Infectious Diseases, 2014, 1, S335-S335.	0.9	0
70	A systematic review of definitions of extreme phenotypes of HIV control and progression. Aids, 2014, 28, 149-162.	2.2	83
71	The genome of the sparganosis tapeworm Spirometra erinaceieuropaeiisolated from the biopsy of a migrating brain lesion. Genome Biology, 2014, 15, 510.	8.8	47
72	Travelâ€Related Infection in European Travelers, EuroTravNet 2011. Journal of Travel Medicine, 2014, 21, 248-254.	3.0	48

#	Article	IF	CITATIONS
73	Leishmaniasis acquired by travellers to endemic regions in Europe: A EuroTravNet multi-centre study. Travel Medicine and Infectious Disease, 2014, 12, 167-172.	3.0	40
74	Illness in Travelers Returned From Brazil: The GeoSentinel Experience and Implications for the 2014 FIFA World Cup and the 2016 Summer Olympics. Clinical Infectious Diseases, 2014, 58, 1347-1356.	5.8	53
75	Seropositivity and Higher Immunoglobulin G Antibody Levels Against Cytomegalovirus Are Associated With Mortality in the Population-Based European Prospective Investigation of Cancer–Norfolk Cohort. Clinical Infectious Diseases, 2013, 56, 1421-1427.	5.8	104
76	A Multinational Outbreak of Histoplasmosis Following a Biology Field Trip in the Ugandan Rainforest. Journal of Travel Medicine, 2013, 20, 83-87.	3.0	39
77	Mortality in Clostridium difficile infection. European Journal of Gastroenterology and Hepatology, 2013, 25, 700-705.	1.6	18
78	Higher Immunoglobulin G Antibody Levels Against Cytomegalovirus Are Associated With Incident Ischemic Heart Disease in the Population-Based EPIC-Norfolk Cohort. Journal of Infectious Diseases, 2012, 206, 1897-1903.	4.0	59
79	Characteristics and Spectrum of Disease Among Ill Returned Travelers from Pre- and Post-Earthquake Haiti: The GeoSentinel Experience. American Journal of Tropical Medicine and Hygiene, 2012, 86, 23-28.	1.4	8
80	Travel-related imported infections in Europe, EuroTravNet 2009. Clinical Microbiology and Infection, 2012, 18, 468-474.	6.0	60
81	Risk factors for mortality in Clostridium difficile infection in the general hospital population: a systematic review. Journal of Hospital Infection, 2012, 82, 1-12.	2.9	59
82	The association between prior infection with five serotypes of Coxsackievirus B and incident type 2 diabetes mellitus in the EPIC-Norfolk study. Diabetologia, 2012, 55, 967-970.	6.3	3
83	Infectious diseases among travellers and migrants in Europe, EuroTravNet 2010. Eurosurveillance, 2012, 17, .	7.0	61
84	Clinical management of Staphylococcus aureus bacteraemia. Lancet Infectious Diseases, The, 2011, 11, 208-222.	9.1	230
85	Report from the second cytomegalovirus and immunosenescence workshop. Immunity and Ageing, 2011, 8, 10.	4.2	35
86	Cushing's syndrome and adrenal axis suppression in a patient treated with ritonavir and corticosteroid eye drops. Aids, 2011, 25, 1337-1339.	2.2	18
87	Treatment with Monoclonal Antibodies against Clostridium difficile Toxins. Yearbook of Medicine, 2010, 2010, 106-108.	0.1	1
88	Continuing diarrhoea after ten days of oral metronidazole or oral vancomycin for presumed, hospital-acquired Clostridium difficile colitis in elderly hospital patients. Journal of Hospital Infection, 2010, 74, 403-405.	2.9	6
89	Travel and migration associated infectious diseases morbidity in Europe, 2008. BMC Infectious Diseases, 2010, 10, 330.	2.9	122
90	Clinical, molecular and epidemiological description of a cluster of community-associated methicillin-resistant Staphylococcus aureus isolates from injecting drug users with bacteraemia. Clinical Microbiology and Infection, 2010, 16, 921-926.	6.0	19

#	Article	IF	Citations
91	Clostridium difficile infection: more known than is realised. Annals of the Royal College of Surgeons of England, 2010, 92, 89-89.	0.6	2
92	Treatment with Monoclonal Antibodies against <i>Clostridium difficile</i> Toxins. New England Journal of Medicine, 2010, 362, 1444-1446.	27.0	7
93	Differential White Blood Cell Count and Type 2 Diabetes: Systematic Review and Meta-Analysis of Cross-Sectional and Prospective Studies. PLoS ONE, 2010, 5, e13405.	2.5	118
94	Illness in Long-Term Travelers Visiting GeoSentinel Clinics. Emerging Infectious Diseases, 2009, 15, 1773-1782.	4.3	101
95	Bone health in HIV infection. British Medical Bulletin, 2009, 92, 123-133.	6.9	12
96	Assessing staff knowledge about Clostridium difficile diarrhoea. Journal of Hospital Infection, 2009, 72, 81-83.	2.9	8
97	Procedural confidence in hospital based practitioners: implications for the training and practice of doctors at all grades. BMC Medical Education, 2009, 9, 2.	2.4	36
98	Fever, a Blue Hand, and Abducens Nerve Paralysis in a Returning Traveler. Journal of Travel Medicine, 2009, 16, 57-59.	3.0	2
99	Furuncular myiasis. BMJ Case Reports, 2009, 2009, bcr0620092026-bcr0620092026.	0.5	5
100	Herpes simplex 1 encephalitis presenting as a brain haemorrhage with normal cerebrospinal fluid analysis: a case report. Journal of Medical Case Reports, 2008, 2, 387.	0.8	11
101	HIV and HIV treatment: effects on fats, glucose and lipids. British Medical Bulletin, 2007, 84, 49-68.	6.9	21
102	An update on malaria prevention, diagnosis and treatment for the returning traveller. Blood Reviews, 2007, 21, 73-87.	5.7	12
103	Colonization or Infection with Multidrug-Resistant Acinetobacter baumannii May Be an Independent Risk Factor for Increased Mortality. Clinical Infectious Diseases, 2006, 43, 1224-1225.	5.8	27
104	A husband and wife with left hand rashes. Lancet Infectious Diseases, The, 2005, 5, 802.	9.1	3
105	Development and Validation of a Dynamic 48-Hour In-Hospital Mortality Risk Stratification for COVID-19 in a UK Teaching Hospital: A Retrospective Cohort Study. SSRN Electronic Journal, 0, , .	0.4	O
106	Point of care SARS-CoV-2 nucleic acid testing in schools improves school attendance. Wellcome Open Research, 0, 7, 8.	1.8	O